Krka receives S&P Global CSA Score

On 24 November 2023, Krka scored 50 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment, with a score of 60 (out of 100) in the governance criteria, 42 (out of 100) in the environmental criteria, and 41 (out of 100) in the social criteria. Krka also obtained a modelled S&P Global ESG Score of 52 (out of 100). As of 24 November 2023, Krka’s S&P Global CSA Score ranked among top 10% companies in the pharmaceutical industry in the S&P Global Corporate Sustainability Assessment.

The received independent score affirms the outlined direction of the Krka Group’s sustainable management practices and ESG governance, where we prioritize our social responsibility and care for the health and well-being of patients. We provide them with access to high-quality, safe, and effective medicines produced in accordance with the highest standards of good manufacturing practice. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity, and transparent operations.

The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group.